Premium
Reimbursement for therapeutic apheresis devices and procedures for using the healthcare insurance system in Japan
Author(s) -
Kusaoi Makio,
Murayama Go,
Tamura Naoto,
Yamaji Ken
Publication year - 2020
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.13550
Subject(s) - reimbursement , medicine , subsidy , public health insurance , apheresis , residence , medical insurance , health insurance , health care , actuarial science , insurance policy , social insurance , family medicine , economic growth , business , demographic economics , economics , immunology , market economy , platelet
The aim of this paper was to explain the insurance coverage status of therapeutic apheresis (excluding CHDF) in Japan, alongside the social system of medical reimbursement and concerns regarding the future sustainability of the healthcare system. Insurance schemes and premiums differed for individuals at different levels in the society (eg, municipal residents, employees, and public servants). Insurance premiums and their rates varied depending on the total household income, the number of people living together, age, and the place of residence. In addition, the medical expense subsidies for children through public expenditure were also described. Japan's generous insurance system and multiple medical expense subsidies provide financial support for patients. With Japan's history of medical expense subsidies based on the policy of supporting intractable diseases, we have established an environment where all citizens can receive therapeutic apheresis when needed if they are affected by a disease for which insurance coverage is indicated.